Reading INCY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track INCY free→Reading INCY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track INCY free→QuarterlyIQ Insights · INCY
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On April 28, 2026 , Incyte Corporation issued a press release announcing financial results for its first fiscal quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 26, 2026, Susanne Schaffert notified Incyte Corporation (the “Company”) that she was resigning from the Company’s Board of Directors (the “Board”), effective as of April 15, 2026. The resignation of Dr. Schaffert, who has been a member of the Company’s Board since 2022, was not the result of any disagreement with the Company on any matter…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 25, 2026, Incyte Corporation (the “Company”) announced title changes for certain current members of its executive leadership team, effective immediately. Pablo J. Cagnoni’s title was changed to President, Incyte and Global Head of Research and Development; Steven H. Stein’s title was changed to Executive Vice President, Chief Medical Offic…
Other Events. On February 27, 2026, the U.S. Food and Drug Administration (“FDA”) issued a Complete Response Letter (“CRL”) for the supplemental Biologics License Application (“sBLA”) for Zynyz® (retifanlimab-dlwr) injection (375mg) for an additional indication for the treatment of adult patients with metastatic non-small cell lung cancer (“NSCLC”) in combination with platinum-based chemotherapy. The sBLA was supported by positive efficacy and safety data from the Phase 3 POD1UM-304 trial ann…
Results of Operations and Financial Condition. On February 10, 2026, Incyte Corporation issued a press release announcing financial results for its fourth fiscal quarter and year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Director Retirement On December 10, 2025, Hervé Hoppenot notified Incyte Corporation (the “Company”) that he was retiring from the Company’s Board of Directors, effective immediately. Mr. Hoppenot, the former Chairman and Chief Executive Officer of the Company, has been a member of the Company’s Board of Directors since 2014. 2 SIGNATURE Pursuant t…
Results of Operations and Financial Condition. On October 28, 2025 , Incyte Corporation issued a press release announcing financial results for its third fiscal quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 30, 2025, the Board of Directors of Incyte Corporation (the “Company”) appointed Thomas Tray, the Company’s current Vice President, Finance and Chief Accounting Officer (principal accounting officer), to the additional position of principal financial officer, effective as of September 16, 2025. Mr. Tray, age 48, joined the Company in J…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 4, 2025, Christiana Stamoulis, Executive Vice President and Chief Financial Officer of Incyte Corporation (the “Company”), notified the Company of her intent to step down from her role to pursue another opportunity, effective September 16, 2025. Ms. Stamoulis will remain at the Company until then to support a smooth transition. The Compan…
Results of Operations and Financial Condition. On July 29, 2025 , Incyte Corporation issued a press release announcing financial results for its second fiscal quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Retirement of President and Chief Executive Officer On June 26, 2025, Incyte Corporation (the “Company”) announced that Hervé Hoppenot retired as President and Chief Executive Officer of the Company effective June 26, 2025. Mr. Hoppenot will continue to serve as a member of the Company’s Board of Directors (the “Board”). Julian C. Baker, Lead Indep…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 2010 Amended and Restated Stock Incentive Plan Amendment At the Annual Meeting of Stockholders of Incyte Corporation (the “Company”) held on June 10, 2025 (the “Annual Meeting”), the stockholders of the Company approved the following amendment to the Company’s Amended and Restated 2010 Stock Incentive Plan (the “SIP”): (i) an increase in the number…
Other Events On May 11, 2025, Incyte Corporation (the “Company”) and Novartis Pharma AG (“Novartis”) entered into a settlement agreement (the “Settlement Agreement”) with respect to litigation initiated by Novartis and relating to the duration of royalty payments owed by the Company to Novartis under the Collaboration and License Agreement dated November 24, 2009, as amended, between the Company and Novartis. As of March 31, 2025, the Company had approximately $537.1 million of accrued royalt…
Results of Operations and Financial Condition. On April 29, 2025 , Incyte Corporation issued a press release announcing financial results for its first fiscal quarter ended March 31, 2025. The full text of the press release is furnished as Exhibit 99.1.
Results of Operations and Financial Condition. On February 10, 2025, Incyte Corporation issued a press release announcing financial results for its fourth fiscal quarter and year ended December 31, 2024. The full text of the press release is furnished as Exhibit 99.1.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 6, 2025, Barry P. Flannelly, Executive Vice President, General Manager, North America of Incyte Corporation (the “Company”), announced his retirement from the Company and stepped down from that role on that date, effective with the commencement of employment of his successor. Dr. Flannelly will remain employed by the Company through July…
Results of Operations and Financial Condition. On October 29, 2024 , Incyte Corporation issued a press release announcing financial results for its third fiscal quarter ended September 30, 2024. The full text of the press release is furnished as Exhibit 99.1.
Results of Operations and Financial Condition. On July 30, 2024 , Incyte Corporation issued a press release announcing financial results for its second fiscal quarter ended June 30, 2024. The full text of the press release is furnished as Exhibit 99.1.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in
Entry Into a Material Definitive Agreement . On June 28, 2024, Incyte Corporation (the “Company”) and its subsidiary, Incyte Holdings Corporation (“Incyte Holdings”), entered into Amendment No. 2 (“Amendment No. 2”) to the Revolving Credit and Guaranty Agreement dated as of August 21, 2021 among the Company, as borrower, Incyte Holdings, as a guarantor, the lenders from time to time party thereto, J.P. Morgan Chase Bank, N.A. as administrative agent, and the other financial institutions party…
Entry Into a Material Definitive Agreement . On May 12, 2024, Incyte Corporation (the “Company”) entered into a stock purchase agreement (the “Purchase Agreement”) with Julian C. Baker, a member of the Company’s board of directors, Felix J. Baker, and entities affiliated with Julian C. and Felix J. Baker, including funds advised by Baker Bros. Advisors LP (collectively, the “Baker Entities”). The Baker Entities, in the aggregate, own 36,833,933 shares of the Company’s common stock, representi…
Results of Operations and Financial Condition. On April 30, 2024 , Incyte Corporation issued a press release announcing financial results for its first fiscal quarter ended March 31, 2024. The full text of the press release is furnished as Exhibit 99.1.
Results of Operations and Financial Condition. On February 13, 2024, Incyte Corporation issued a press release announcing financial results for its fourth fiscal quarter and year ended December 31, 2023. The full text of the press release is furnished as Exhibit 99.1.
Results of Operations and Financial Condition. On October 31, 2023 , Incyte Corporation issued a press release announcing financial results for its third fiscal quarter ended September 30, 2023. The full text of the press release is furnished as Exhibit 99.1.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . On September 8, 2023, Maria E. Pasquale, Executive Vice President, General Counsel and Corporate Secretary of Incyte Corporation (the “Company”), notified the Company of her intention to retire effective November 1, 2023. Ms. Pasquale’s roles as Executive Vice President, General Counsel and Corporate Secretary of the Company may end earlier than h…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.